INNOVIVA, INC. (INVA) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 258.45M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 1.70B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | $258.45M | (m) | (m) | $1.70B | (m) |
| 2026-03-31 | (m) | (m) | (m) | $258.10M | (m) | (m) | $1.84B | (m) |
| 2025-12-31 | (m) | (m) | (m) | $257.73M | (m) | (m) | $1.64B | (m) |
| 2025-09-30 | (m) | (m) | (m) | $257.38M | (m) | (m) | $1.43B | (m) |
| 2025-06-30 | (m) | (m) | (m) | $257.02M | (m) | (m) | $1.33B | (m) |
| 2025-03-31 | (m) | (m) | (m) | $256.67M | (m) | (m) | $1.25B | (m) |
| 2024-12-31 | (m) | (m) | (m) | $256.32M | (m) | (m) | $1.30B | (m) |
| 2024-09-30 | (m) | (m) | (m) | $255.97M | (m) | (m) | $1.23B | (m) |
| 2024-06-30 | (m) | (m) | (m) | $447.28M | (m) | (m) | $1.22B | (m) |
| 2024-03-31 | (m) | (m) | (m) | $446.76M | (m) | (m) | $1.27B | (m) |
| 2023-12-31 | (m) | (m) | (m) | $446.23M | (m) | (m) | $1.24B | (m) |
| 2023-09-30 | (m) | (m) | (m) | $445.72M | (m) | (m) | $1.19B | (m) |
| 2023-06-30 | (m) | (m) | (m) | $445.20M | (m) | (m) | $1.12B | (m) |
| 2023-03-31 | (m) | (m) | (m) | $444.69M | (m) | (m) | $1.13B | (m) |
| 2022-12-31 | (m) | (m) | (m) | $444.18M | (m) | (m) | $1.23B | (m) |
| 2022-09-30 | (m) | (m) | (m) | $443.68M | (m) | $301.07M | $1.33B | (m) |
| 2022-06-30 | (m) | (m) | (m) | $443.18M | (m) | (m) | $1.14B | (m) |
| 2022-03-31 | (m) | (m) | (m) | $442.73M | (m) | (m) | $1.11B | (m) |
| 2021-12-31 | (m) | (m) | (m) | $394.65M | (m) | (m) | $926.39M | (m) |
| 2021-09-30 | (m) | (m) | (m) | $392.30M | (m) | (m) | $887.24M | (m) |
| 2021-06-30 | (m) | (m) | (m) | $389.99M | (m) | (m) | $789.15M | (m) |
| 2021-03-31 | (m) | (m) | (m) | $387.73M | (m) | (m) | $1.09B | (m) |
| 2020-12-31 | (m) | (m) | (m) | $385.52M | (m) | $246.49M | $999.57M | (m) |
| 2020-09-30 | (m) | (m) | (m) | $383.35M | (m) | $479.19M | $922.26M | (m) |
| 2020-06-30 | (m) | (m) | (m) | $381.23M | (m) | $417.15M | $879.62M | (m) |
| 2020-03-31 | (m) | (m) | (m) | $379.15M | (m) | $383.95M | $788.01M | (m) |
| 2019-12-31 | (m) | (m) | (m) | $377.12M | (m) | $350.85M | $724.83M | (m) |
| 2019-09-30 | (m) | (m) | (m) | $388.64M | (m) | $297.20M | $675.95M | (m) |
| 2019-06-30 | (m) | (m) | (m) | $386.68M | (m) | $249.66M | $642.31M | (m) |
| 2019-03-31 | (m) | (m) | (m) | $384.74M | (m) | $192.18M | $590.11M | (m) |
| 2018-12-31 | (m) | (m) | (m) | $382.86M | (m) | $114.91M | $548.19M | (m) |
| 2018-09-30 | (m) | (m) | (m) | $381.00M | (m) | $55.48M | $277.69M | (m) |
| 2018-06-30 | (m) | (m) | (m) | $486.53M | (m) | $107.54M | $338.69M | (m) |
| 2018-03-31 | (m) | (m) | (m) | $484.59M | (m) | $56.46M | $276.75M | (m) |
| 2017-12-31 | (m) | (m) | (m) | $574.36M | (m) | $129.07M | $367.34M | (m) |
| 2017-09-30 | (m) | (m) | (m) | $578.45M | (m) | $168.19M | $390.97M | (m) |
| 2017-06-30 | (m) | (m) | $15.18M | $638.71M | (m) | $135.63M | $372.02M | (m) |
| 2017-03-31 | (m) | (m) | (m) | $702.33M | (m) | $169.81M | $391.87M | (m) |
| 2016-12-31 | (m) | (m) | $7.75M | $708.34M | (m) | $150.43M | $379.00M | (m) |
| 2016-09-30 | (m) | (m) | (m) | $719.45M | (m) | $148.97M | $370.54M | (m) |
| 2016-06-30 | (m) | (m) | $3.27M | $722.29M | (m) | $153.87M | $378.11M | (m) |
| 2016-03-31 | (m) | (m) | (m) | $734.51M | (m) | $168.19M | $387.83M | (m) |
| 2015-12-31 | (m) | (m) | (m) | $733.13M | (m) | $187.28M | $408.93M | (m) |
| 2015-09-30 | (m) | (m) | (m) | $744.09M | (m) | $206.19M | $437.63M | (m) |
| 2015-06-30 | (m) | (m) | (m) | $738.47M | (m) | $229.26M | $462.09M | (m) |
| 2015-03-31 | (m) | (m) | (m) | $732.06M | (m) | $251.14M | $488.70M | (m) |
| 2014-12-31 | (m) | (m) | (m) | $725.64M | (m) | $240.50M | $521.65M | (m) |
| 2014-09-30 | (m) | (m) | (m) | $705.11M | (m) | $263.11M | $553.71M | (m) |
| 2013-12-31 | (m) | (m) | (m) | $287.50M | (m) | $465.13M | $681.25M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |